5 Key Takeaways

• 1

  Roche's fenebrutinib met the primary endpoint in a phase 3 trial against OCREVUS for primary progressive multiple sclerosis.

• 2

  Fenebrutinib showed a 12% numerical reduction in disability progression risk compared to OCREVUS, with early treatment effects observed.

• 3

  The strongest treatment effect of fenebrutinib was a 26% reduction in worsening upper limb function compared to OCREVUS.

• 4

  Safety profiles were similar for both treatments, with common adverse events including infections and transient liver enzyme elevations.

• 5

  Roche plans to submit regulatory filings for fenebrutinib in PPMS and relapsing MS following additional study results expected in 2026.